EGFR and non-small cell lung carcinoma: Testing for epidermal growth factor receptor (EGFR) mutations is an essential step during therapeutic decision-making for patients newly diagnosed with advanced non-small cell lung cancer (NSCLC), especially considering the remarkable clinical outcomes of EGFR-tyrosine kinase inhibitor (TKI) treatments [1].